# A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

> **NCT06232096** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 154 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** MBS314 Injection

## Key facts

- **NCT ID:** NCT06232096
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2026-02
- **Final completion:** 2028-03
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232096, "A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06232096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*